Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel [12]

Acta Dermato-Venereologica

Volumn 87, Issue 2, 2007, Pages 188-189

  Rivers, Jason K ^a   Wolf, John ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; PLACEBO;

ACTINIC KERATOSIS; APPLICATION SITE IRRITATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRY SKIN; FOLLOW UP; GEL; HUMAN; LETTER; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DOUBLE-BLIND METHOD; HUMANS; KERATOSIS;

EID: 34047184786     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0213     Document Type: Letter

References (15)

1. Drake LA, Ceilley RI, Cornelison RL, Dobes WL, Dorner W, Goltz RW, et al. Guidelines of care for actinic keratoses. J Am Acad Dermatol 1995; 32: 95-98.
2. Cohn BA. From sunlight to actinic keratosis to squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 143-144.
3. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558-566.
4. Freemantle C, Alam CAS, Brown JR, Seed MP, Willoughby DA. The modulation of granulomatous tissue and tumour angiogenesis by diclofenac in combination with hyaluronan (HYAL EX-0001). Int J Tiss Reac 1995; 17: 157-166.
5. Brown MP, Hanpanitcharoen M, Martin GP. An in vitro investigation into the effect of glycosaminoglycans on the skin partitioning and deposition of NSAIDs. Int J Pharm 2001; 225: 113-121.
6. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-1242.
7. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
8. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
9. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze™). J Drugs Dermatol 2004; 3: 401-407.
10. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australasian J Derm 2003; 44: 40-15.
11. Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-473.
12. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-555.
13. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-721.
14. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000.
15. 5-fluorouracil SmPC. 2005 November 7. Available from: URL: www.medsafe.govt.nz/Profs/datasheet/e/Efudixcrl. htm [last accessed 9 Jan 2007]